-+ 0.00%
-+ 0.00%
-+ 0.00%

Citigroup Maintains Buy on Summit Therapeutics, Raises Price Target to $43

Benzinga·09/29/2026 17:52:31
Listen to the news
Citigroup analyst Yigal Nochomovitz maintains Summit Therapeutics (NASDAQ:SMMT) with a Buy and raises the price target from $40 to $43.